Seres Therapeutics (NASDAQ:MCRB) and BELLUS Health (NASDAQ:BLU) Head to Head Review

BELLUS Health (NASDAQ:BLU) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

BELLUS Health has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.5, suggesting that its share price is 350% more volatile than the S&P 500.

Earnings and Valuation

This table compares BELLUS Health and Seres Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BELLUS Health $30,000.00 4,332.11 -$25.97 million ($0.55) -3.91
Seres Therapeutics $34.51 million 55.80 -$70.28 million ($1.20) -21.04

BELLUS Health has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BELLUS Health and Seres Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BELLUS Health 0 0 0 0 N/A
Seres Therapeutics 0 1 6 0 2.86

Seres Therapeutics has a consensus price target of $34.75, suggesting a potential upside of 37.62%. Given Seres Therapeutics’ higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than BELLUS Health.

Insider & Institutional Ownership

61.1% of BELLUS Health shares are owned by institutional investors. Comparatively, 94.4% of Seres Therapeutics shares are owned by institutional investors. 24.2% of BELLUS Health shares are owned by company insiders. Comparatively, 4.8% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares BELLUS Health and Seres Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BELLUS Health -159,313.63% -32.57% -30.64%
Seres Therapeutics -262.34% N/A -64.79%


Seres Therapeutics beats BELLUS Health on 7 of the 13 factors compared between the two stocks.

About BELLUS Health

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

About Seres Therapeutics

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with's FREE daily email newsletter.